Journey Medical Corporation to Participate in September 2025 Investor Conferences
Journey Medical Corporation (NASDAQ:DERM), a commercial-stage pharmaceutical company focused on marketing FDA-approved dermatological treatments, has announced its participation in two upcoming investor conferences in September 2025.
CEO Claude Maraoui will attend the H.C. Wainwright 27th Annual Global Investment Conference on September 8, participating in a fireside chat and one-on-one meetings. Additionally, the company will participate in the Lake Street Capital Markets 9th Annual Best Ideas Growth Conference on September 11, featuring one-on-one meetings with investors.
Journey Medical Corporation (NASDAQ:DERM), azienda farmaceutica in fase commerciale specializzata nella commercializzazione di trattamenti dermatologici approvati dalla FDA, ha annunciato la sua partecipazione a due prossimi incontri per investitori a settembre 2025.
Il CEO Claude Maraoui parteciperà al H.C. Wainwright 27th Annual Global Investment Conference l’8 settembre, prendendo parte a una fireside chat e a incontri one-to-one. Inoltre, la società sarà presente al Lake Street Capital Markets 9th Annual Best Ideas Growth Conference l’11 settembre, con sessioni individuali di incontro con gli investitori.
Journey Medical Corporation (NASDAQ:DERM), una compañía farmacéutica en fase comercial centrada en la comercialización de tratamientos dermatológicos aprobados por la FDA, ha anunciado su participación en dos próximas conferencias para inversores en septiembre de 2025.
El CEO Claude Maraoui asistirá al H.C. Wainwright 27th Annual Global Investment Conference el 8 de septiembre, participando en una charla informal y en reuniones uno a uno. Además, la compañía participará en el Lake Street Capital Markets 9th Annual Best Ideas Growth Conference el 11 de septiembre, con reuniones individuales con inversores.
Journey Medical Corporation (NASDAQ:DERM)는 FDA 승인 피부과 치료제의 마케팅에 주력하는 상업 단계 제약사로, 2025년 9월에 열리는 두 회의형 투자자 콘퍼런스에 참가한다고 발표했습니다.
CEO Claude Maraoui는 9월 8일 H.C. Wainwright 27th Annual Global Investment Conference에 참석해 파이어사이드 채트와 1:1 미팅에 참여합니다. 또한 회사는 9월 11일 열리는 Lake Street Capital Markets 9th Annual Best Ideas Growth Conference에도 참가해 투자자들과 일대일 미팅을 진행할 예정입니다.
Journey Medical Corporation (NASDAQ:DERM), une société pharmaceutique en phase commerciale spécialisée dans la commercialisation de traitements dermatologiques approuvés par la FDA, a annoncé sa participation à deux conférences pour investisseurs prévues en septembre 2025.
Le PDG Claude Maraoui assistera à la H.C. Wainwright 27th Annual Global Investment Conference le 8 septembre, prenant part à une discussion informelle et à des rencontres individuelles. Par ailleurs, la société participera à la Lake Street Capital Markets 9th Annual Best Ideas Growth Conference le 11 septembre, avec des réunions en tête‑à‑tête avec des investisseurs.
Journey Medical Corporation (NASDAQ:DERM), ein in der kommerziellen Phase befindliches Pharmaunternehmen, das sich auf die Vermarktung von von der FDA zugelassenen dermatologischen Behandlungen spezialisiert hat, gab seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2025 bekannt.
CEO Claude Maraoui wird am 8. September an der H.C. Wainwright 27th Annual Global Investment Conference teilnehmen und in einer Fireside-Chat-Runde sowie in Einzelgesprächen vertreten sein. Zudem nimmt das Unternehmen am 11. September an der Lake Street Capital Markets 9th Annual Best Ideas Growth Conference teil, mit One-on-One-Gesprächen mit Investoren.
- None.
- None.
SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2025 investor conferences.
Details of the events are as follows:
H.C. Wainwright 27th Annual Global Investment Conference
Date and Time: Monday, September 8, 2025, at 1:30 p.m. ET
Location: New York City
Format: Fireside Chat and 1x1 Meetings
Lake Street Capital Markets 9th Annual Best Ideas Growth (BIG9) Conference
Date: Thursday, September 11, 2025
Location: New York City
Format: 1x1 Meetings
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.
Company Contact:
Jaclyn Jaffe
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
FAQ
When is Journey Medical's (DERM) presentation at the H.C. Wainwright Conference 2025?
Who will represent Journey Medical (DERM) at the September 2025 investor conferences?
What type of meetings will Journey Medical (DERM) participate in at the Lake Street Conference?
Where are the Journey Medical (DERM) investor conferences being held in September 2025?
